Search

Your search keyword '"Ludolph, Albert C."' showing total 310 results

Search Constraints

Start Over You searched for: Author "Ludolph, Albert C." Remove constraint Author: "Ludolph, Albert C." Database Academic Search Index Remove constraint Database: Academic Search Index
310 results on '"Ludolph, Albert C."'

Search Results

1. Clinical spreading of muscle weakness in amyotrophic lateral sclerosis (ALS): a study in 910 patients.

2. Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post‐onset ΔFS for study design and medical practice.

3. Clinical and paraclinical features of first unprovoked seizures in the elderly.

4. Effect of High-Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis.

5. Screening instruments of cognition: The relation of the mini-mental state examination to the Edinburgh cognitive and behavioural ALS screen in amyotrophic lateral sclerosis.

6. Short-term and long-term effects of immunoadsorption in refractory chronic inflammatory demyelinating polyneuropathy: a prospective study in 17 patients.

7. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.

8. New Perspectives in Radiological and Radiopharmaceutical Hybrid Imaging in Progressive Supranuclear Palsy: A Systematic Review.

9. Diffusion Tensor Imaging in Amyotrophic Lateral Sclerosis: Machine Learning for Biomarker Development.

10. Guidelines for preclinical animal research in ALS/MND: A consensus meeting.

11. MRI-based functional neuroimaging in ALS: An update.

12. Brain metabolites in definite amyotrophic lateral sclerosis.

13. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: Report on the 142nd ENMC international workshop.

15. Motor protein diseases of the nervous system.

16. Preclinical Trials – An Update on Translational Research in ALS.

17. Hereditary motor neuropathies and motor neuron diseases: which is which.

18. Ifosfamide encephalopathy presenting with asterixis

19. HARM revisited: Etiology of subarachnoid hyperintensities in brain FLAIR MRI.

20. NEUROTOXIC MECHANISMS OF DEGENERATION IN MOTOR NEURON DISEASES*.

21. Amyotrophic Lateral Sclerosis and Glutamate.

22. Can we turn mice into men?: An Editorial for 'Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: a systematic review and meta‐analysis' page 284.

23. Quantification of blood glial fibrillary acidic protein using a second-generation microfluidic assay. Validation and comparative analysis with two established assays.

24. Neuropeptide FF (NPFF)-positive nerve cells of the human cerebral cortex and white matter in controls, selected neurodegenerative diseases, and schizophrenia.

26. Myelitis as a side effect of tofersen therapy in SOD1-associated ALS.

27. The central pattern of weakness of ALS: Morphological correlates in whole‐body muscle MRI.

28. Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis—insights from a completed randomized controlled trial with rasagiline.

29. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis.

30. One third of physicians discuss exit strategies with patients with amyotrophic lateral sclerosis: Results from nationwide surveys among German and Polish neurologists.

31. Neurological manifestation of HEV infection: still a rare disease entity?

32. AI-assisted quantification of hypothalamic atrophy in amyotrophic lateral sclerosis by convolutional neural network-based automatic segmentation.

33. Skeletal muscle in amyotrophic lateral sclerosis.

36. Juxtacortical lesions are associated with seizures in cerebral small vessel disease.

37. Non‐invasive ventilation and hypercapnia‐associated symptoms in amyotrophic lateral sclerosis.

38. Motor neuron disease: urgently needed-biomarkers for amyotrophic lateral sclerosis.

40. Neurodegeneration or dysfunction in Phelan-McDermid syndrome? A multimodal approach with CSF and computational MRI.

41. Presymptomatic grey matter alterations in ALS kindreds: a computational neuroimaging study of asymptomatic C9orf72 and SOD1 mutation carriers.

42. Religiosity in patients with amyotrophic lateral sclerosis, a cross-country comparison.

43. Determining impairment in the Swedish, Polish and German ECAS: the importance of adjusting for age and education.

44. The fecal microbiome of ALS patients.

45. Impaired ATF3 signaling involves SNAP25 in SOD1 mutant ALS patients.

46. Patterns of synaptic loss in human amyotrophic lateral sclerosis spinal cord: a clinicopathological study.

47. Lipids and amyotrophic lateral sclerosis: A two‐sample Mendelian randomization study.

48. Quality of life and depression in patients with amyotrophic lateral sclerosis – does the country of origin matter?

49. Shank2 identifies a subset of glycinergic neurons involved in altered nociception in an autism model.

50. Loss of hypothalamic MCH decreases food intake in amyotrophic lateral sclerosis.

Catalog

Books, media, physical & digital resources